Bio-Rad Laboratories reported second-quarter 2025 net sales of $651.6 million, an increase of 2.1% compared to $638.5 million in Q2 2024. On a currency-neutral basis, quarterly sales increased by 1.0%, primarily driven by higher sales of process chromatography products.
The Life Science segment saw a 3.8% currency-neutral sales increase, while Clinical Diagnostics sales decreased by 0.7% currency-neutral, mainly due to lowered reimbursements for diabetes testing in China. Non-GAAP net income for Q2 2025 was $71.0 million, or $2.61 per diluted share, compared to $88.3 million, or $3.11 per diluted share, in Q2 2024.
Bio-Rad updated its full-year 2025 financial outlook, now expecting non-GAAP currency-neutral revenue growth of approximately 0% to 1.0%, an improvement from its prior estimated range of a 1.0% decline to 1.5% growth. The non-GAAP operating margin is now estimated to be approximately 12.0% to 13.0%, up from the prior expectation of 10.0% to 12.0%.
The GAAP net income for the second quarter of 2025 was $317.8 million, or $11.67 per share, a significant improvement from a net loss of $(2,165.5) million, or $(76.26) per share, in Q2 2024. This substantial change was primarily due to the fair market value adjustment of the company's investment in Sartorius AG.
The company also noted the completion of the Stilla Technologies acquisition and the recent launch of its QX Continuum™ system, complemented by the acquired QX700™ series instruments. These developments expand Bio-Rad's Droplet Digital™ PCR offering, enhancing its market position in genomics research and applied science.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.